These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 32738042)

  • 21. Sequential comparisons of one-month and three-month depot leuprolide regimens in central precocious puberty.
    Badaru A; Wilson DM; Bachrach LK; Fechner P; Gandrud LM; Durham E; Wintergerst K; Chi C; Klein KO; Neely EK
    J Clin Endocrinol Metab; 2006 May; 91(5):1862-7. PubMed ID: 16449344
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of depot leuprolide acetate dose-adequacy for central precocious puberty.
    Cook JS; Doty KL; Conn PM; Hansen JR
    J Clin Endocrinol Metab; 1992 May; 74(5):1206-9. PubMed ID: 1569169
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Changes in body mass index during gonadotropin-releasing hormone agonist treatment for central precocious puberty and early puberty.
    Lee HS; Yoon JS; Roh JK; Hwang JS
    Endocrine; 2016 Nov; 54(2):497-503. PubMed ID: 27444748
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of gonadotropin-releasing hormone analog on ovarian reserve in children with central precocious puberty.
    Tao Y; Si C; Li H; Han J; Hou H; Yang M
    Ann Palliat Med; 2020 Jan; 9(1):53-62. PubMed ID: 32005063
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetic and exposure-response analyses of leuprolide following administration of leuprolide acetate 3-month depot formulations to children with central precocious puberty.
    Mostafa NM; Hosmane B; Larsen LM; Chwalisz K; Chiu YL; Pradhan RS
    Clin Drug Investig; 2014 Jul; 34(7):441-8. PubMed ID: 24756362
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of gonadotrophin suppression in girls treated with GnRH analogue for central precocious puberty; validity of single luteinizing hormone measurement after leuprolide acetate injection.
    Demirbilek H; Alikasifoglu A; Gonc NE; Ozon A; Kandemir N
    Clin Endocrinol (Oxf); 2012 Jan; 76(1):126-30. PubMed ID: 21790701
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of leuprolide acetate response patterns in the early diagnosis of pubertal disorders: comparison with the gonadotropin-releasing hormone test.
    Ibáñez L; Potau N; Zampolli M; Virdis R; Gussinyé M; Carrascosa A; Saenger P; Vicens-Calvet E
    J Clin Endocrinol Metab; 1994 Jan; 78(1):30-5. PubMed ID: 7507123
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum luteinizing hormone rises within minutes after depot leuprolide injection: implications for monitoring therapy.
    Bhatia S; Neely EK; Wilson DM
    Pediatrics; 2002 Feb; 109(2):E30. PubMed ID: 11826240
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A dose finding study of a super long-acting luteinizing hormone-releasing hormone analog (leuprolide acetate depot, TAP-144-SR) in the treatment of central precocious puberty. The TAP-144-SR CPP Study Group.
    Tanaka T; Hibi I; Kato K; Saito S; Shimizu N; Suwa S; Nakajima H
    Endocrinol Jpn; 1991 Aug; 38(4):369-76. PubMed ID: 1839379
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Elevated Random Luteinizing Hormone is an Unreliable Indicator for Pubertal Suppression in Girls Treated with Monthly Leuprolide for Idiopathic Central Precocious Puberty.
    Wiromrat P; Panamonta O
    J Clin Res Pediatr Endocrinol; 2019 Sep; 11(3):227-233. PubMed ID: 30592192
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of three doses of leuprolide acetate in the treatment of central precocious puberty: preliminary results.
    Mericq V; Lammoglia JJ; Unanue N; Villaroel C; Hernández MI; Avila A; Iñiguez G; Klein KO
    Clin Endocrinol (Oxf); 2009 Nov; 71(5):686-90. PubMed ID: 19302581
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term outcomes after gonadotropin-releasing hormone agonist treatment in boys with central precocious puberty.
    Shim YS; Lim KI; Lee HS; Hwang JS
    PLoS One; 2020; 15(12):e0243212. PubMed ID: 33301485
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-Acting Gonadotropin-Releasing Hormone Analogues for Central Precocious Puberty, Including 45-Mg 6-Month Subcutaneous Leuprolide Acetate: Use for Treatment and Treatment Monitoring.
    Silverman LA; Geffner ME; Benson M
    Horm Res Paediatr; 2024 Apr; ():1-8. PubMed ID: 38653206
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased final adult height by gonadotropin-releasing hormone agonist in girls with idiopathic central precocious puberty.
    Lee HS; Yoon JS; Park KJ; Hwang JS
    PLoS One; 2018; 13(8):e0201906. PubMed ID: 30133462
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and Safety of Leuprolide Acetate 6-Month Depot for the Treatment of Central Precocious Puberty: A Phase 3 Study.
    Klein KO; Mauras N; Nayak S; Sunil B; Martinez-Placencia BM; Dragnic S; Ballina M; Zhou Q; Kansra AR
    J Endocr Soc; 2023 Jun; 7(7):bvad071. PubMed ID: 37334213
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Suppression of gonadotropin secretion by a long-acting gonadotropin-releasing hormone analog (leuprolide acetate, Lupron Depot) in children with precocious puberty.
    Kappy M; Stuart T; Perelman A; Clemons R
    J Clin Endocrinol Metab; 1989 Nov; 69(5):1087-9. PubMed ID: 2507570
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment with Depot Leuprolide Acetate in Girls with Idiopathic Precocious Puberty: What Parameter should be Used in Deciding on the Initial Dose?
    Vurallı D; Alikaşifoğlu A; İyigün İ; Canoruç D; Ozon A; Gönç N; Kandemir N
    J Clin Res Pediatr Endocrinol; 2020 Mar; 12(1):37-44. PubMed ID: 31347350
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sterile abscess formation in response to two separate branded long-acting gonadotropin-releasing hormone agonists.
    Miller BS; Shukla AR
    Clin Ther; 2010 Sep; 32(10):1749-51. PubMed ID: 21194598
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Three-month sustained-release triptorelin (11.25 mg) in the treatment of central precocious puberty.
    Carel JC; Blumberg J; Seymour C; Adamsbaum C; Lahlou N;
    Eur J Endocrinol; 2006 Jan; 154(1):119-24. PubMed ID: 16382000
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of domestic leuprorelin in girls with idiopathic central precocious puberty: a multicenter, randomized, parallel, controlled trial.
    Li WJ; Gong CX; Guo MJ; Xing J; Li T; Song WH; Luo XP; Wu D; Liang JP; Cao BY; Gu Y; Su C; Liang XJ; Liu M; Wang R; Li FT
    Chin Med J (Engl); 2015 May; 128(10):1314-20. PubMed ID: 25963350
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.